News

Eltrombopag and Cyclosporin A Demonstrate Beneficial Outcomes as Frontline Treatment for Patients With Severe Aplastic Anemia

03/18/2024

Jordan Kadish

According to the phase 2 SOAR trial, eltrombopag plus cyclosporin A demonstrated beneficial outcomes as a frontline treatment for patients with severe aplastic anemia, including activity and no new safety symbols.

According to the phase 2 SOAR...

03/18/2024

Oncology

News

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Potential Minor Criteria for Polycythemia Vera Diagnosis

08/22/2023

Amber Denham

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio showed promise as potential minor diagnostic criteria for patients with polycythemia vera, according to a retrospective study.

Neutrophil-to-lymphocyte ratio...

08/22/2023

Oncology

News

Optimizing Hydroxyurea Management Among Patients With Polycythemia Vera

08/09/2023

Amber Denham

More optimal hydroxyurea management and poor-responder intervention for patients with polycythemia vera would be beneficial, according to a recent retrospective real-world analysis.

More optimal hydroxyurea...

08/09/2023

Oncology

News

Alternative Dosing Regimen of Ropeginterferon Alfa-2b Demonstrates High Efficacy, Tolerability Among Patients With Polycythemia Vera

07/14/2023

Gina Tomaine

A new dosing regimen of ropeginterferon alfa-2b was found to be highly effective and well-tolerated among patients with polycythemia vera, according to a phase 2 study.

A new dosing regimen of...

07/14/2023

Oncology

News

Ruxolitinib Treatment Effective, Safe for Patients With Newly Diagnosed Polycythemia Vera

05/05/2023

Gina Tomaine

Ruxolitinib therapy was found to be feasible, well-tolerated, and efficient among patients with untreated polycythemia vera, according to the futility analysis of a phase 2b trial.

Ruxolitinib therapy was found to...

05/05/2023

Oncology

News

Momelotinib Improved Anemia Measures, Spleen Response, and Overall Safety Among Patients With Myelofibrosis

04/21/2023

Jordan Kadish

According to a phase 3 trial, momelotinib, a first-class JAK1 and JAK2 inhibitor, improved anemia measures, spleen response, and overall safety among patients with myelofibrosis compared to other JAK inhibitors.

According to a phase 3 trial,...

04/21/2023

Oncology

News

Low-Intensity Regimens for Sickle Cell Disease Transplantation Associated With Risk of Secondary Neoplasms

03/13/2023

Jordan Kadish

Low-intensity regimens for sickle cell disease transplantations were associated with a higher risk of secondary neoplasms, including leukemia and myelodysplastic syndromes.

Low-intensity regimens for...

03/13/2023

Oncology

Conference Coverage

Ropeginterferon Alfa-2b Yielded Higher Hematologic and Molecular Response Rates Among Patients With Low-Risk vs High-Risk Polycythemia Vera

02/27/2023

Jordan Kadish

A phase 3 study found that implementation of ropeginterferon alfa-2b yielded significantly higher hematologic and molecular response rates among patients with polycythemia vera compared with hydroxyurea or other available treatments.

A phase 3 study found that...

02/27/2023

Oncology

Conference Coverage

Ropeginterferon Alfa-2b Yielded Higher Hematologic and Molecular Response Rates Among Patients With Low-Risk vs High-Risk Polycythemia Vera

02/27/2023

Jordan Kadish

A phase 3 study found that...

02/27/2023

Oncology

News

Increased Likelihood of Blood Clots in Patients With Non-Proliferative CBC Thrombosis Myeloproliferative Neoplasms

02/27/2023

Jordan Kadish

A study found that patients with non-proliferative CBC thrombosis MPNs and driver mutations with non-splanchnic involvement have an increased risk for recurrent blood clots and progression of the disorder than those with splanchnic...

A study found that patients with...

02/27/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology